Matthew Barcus
Stock Analyst at Chardan Capital
(2.44)
# 2,445
Out of 5,140 analysts
21
Total ratings
25%
Success rate
31.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $6.32 | +58.23% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $21.74 | +24.20% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.60 | +1,072.33% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $26.02 | +22.98% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.61 | +36,137.85% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.17 | +184.36% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $24.87 | -67.83% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $6.32
Upside: +58.23%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $21.74
Upside: +24.20%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.60
Upside: +1,072.33%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $26.02
Upside: +22.98%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.61
Upside: +36,137.85%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.17
Upside: +184.36%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $24.87
Upside: -67.83%